ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells

Chen, Yuqiu; Xu, Jiawei; Pan, Wang; Xu, Xiaofan; Ma, Xueping; Chu, Ya'nan; Wang, Lu; Pang, Shuyun; Li, Yujiao; Zou, Bingjie*; Zhou, Guohua*; Gu, Jun*南方医科大学; 南京大学
Thoracic Cancer2022-7DOI: 10.1111/1759-7714.14474
2被引5阅读
引用收藏
分享

摘要

Purpose The aim of this study was to explore the role of galectin-3 in human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells and the potential mechanism. Methods Kaplan-Meier (KM)-plot and The Cancer Genome Atlas (TCGA) databases were used to study the role of galectin-3 in the prognosis of HER2-positive breast cancer. The effects of galectin-3 on cell proliferation, migration, invasion, and colony formation ability in HER2-positive breast cancer cells were examined. The relationship between galectin-3 and important components in the HER2 pathways, including HER2, epidermal growth factor receptor (EGFR), protein kinase B (AKT), and phosphatase and tensin homolog (PTEN), was further studied. Lentivirus and CRISPR/Cas9 were used to construct stable cell lines. Cell counting kit-8 (CCK-8) and apoptosis assays were used to study the relationship between galectin-3 and trastuzumab. The effect of galectin-3 on cell stemness was studied by mammosphere formation assay. The effects of galectin-3 on stemness biomarkers and the Notch1 pathway were examined. Tumorigenic models were used to evaluate the effects of galectin-3 on tumorigenesis and the therapeutic effect of trastuzumab in vivo. Results HER2-positive breast cancer patients with a high expression level of LGALS3 (the gene encoding galectin-3) messenger RNA (mRNA) showed a poor prognosis. Galectin-3 promoted cancer malignancy through phosphoinositide 3-kinase (PI3K)/AKT signaling pathway activation and upregulated stemness by activating the Notch1 signaling pathway in HER2-positive breast cancer cells. These two factors contributed to the enhancement of trastuzumab resistance in cells. Knockout of LGALS3 had a synergistic therapeutic effect with trastuzumab both in vitro and in vivo. Conclusions Galectin-3 may represent a prognostic predictor and therapeutic target for HER2-positive breast cancer.

学科与关键词

关键词
cancer cell stemnessgalectin-3HER2-positive breast cancertrastuzumab resistance
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Thoracic Cancer
发表日期
2022-07
卷期
第 13 卷, 第 13 期
页码
1961-1973
DOI
10.1111/1759-7714.14474
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
Jiangsu Province Science and Technology Project of China [BE2017726]; National Natural Science Foundation of China [61871403, 82001422]; Natural Science Foundation of Jiangsu Province Youth Project [BK20200274]

作者

  • C

    Chen, Yuqiu (第一作者)

    nanjing univ

  • X

    Xu, Jiawei

    nanjing univ

查看全部 12 位作者收起作者
  • P

    Pan, Wang

    nanjing univ

  • X

    Xu, Xiaofan

    nanjing univ

  • M

    Ma, Xueping

    nanjing univ

  • C

    Chu, Ya'nan

    nanjing univ

  • W

    Wang, Lu

    nanjing univ

  • P

    Pang, Shuyun

    nanjing univ

  • L

    Li, Yujiao

    nanjing univ

  • Z

    Zou, Bingjie (通讯)

    china pharmaceut univ

  • Z

    Zhou, Guohua (通讯)

    nanjing univ · southern med univ

  • G

    Gu, Jun (通讯)

    nanjing univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417